EG017 / GeneScience - LARVOL DELTA

To Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer. (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Phase classification: P1a/1b ➔ P1

Phase classification • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

A Phase IIStudy to Evaluate the Efficacy and Safety of EG017 Ointment for the Treatment of Dry Eye in Postmenopausal Women (clinicaltrials.gov) - P2 | N=240 | Recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

New P2 trial • Dry Eye Disease • Ophthalmology

To Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer. (clinicaltrials.gov) - P1a/1b | N=70 | Recruiting | Sponsor: GeneScience Pharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2026 ➔ Jan 2026 | Trial primary completion date: Mar 2026 ➔ Nov 2025

Enrollment open • Metastases • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor